Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -238.9%. (2022–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Market Cap | $3M | $3M | $3M | $44M | — | — |
| Enterprise Value | $-3896313 | $-4189466 | $-6045509 | $37M | — | — |
| P/E Ratio → | -0.12 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.33 | 0.48 | 0.38 | 5.79 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| ROE | -238.9% | -238.9% | -145.1% | -373.0% | -152.9% | -680.2% |
| ROA | -192.1% | -192.1% | -118.8% | -300.4% | -136.4% | -649.3% |
| ROIC | — | — | — | — | — | — |
| ROCE | -243.4% | -243.4% | -138.5% | -259.4% | -152.9% | -693.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.13 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.19 | -1.13 | -1.00 | -1.34 | -1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | -63.83 | -194.27 | — | -62.33 |
Net cash position: cash ($7M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Current Ratio | 4.45 | 4.45 | 5.63 | 12.09 | 3.91 | 22.02 |
| Quick Ratio | 4.45 | 4.45 | 5.63 | 12.09 | 3.91 | 22.02 |
| Cash Ratio | 4.11 | 4.11 | 5.35 | 11.08 | 3.91 | 21.92 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $343655 | $84095 | $34824 | $894952 | $894952 |
Clinical trial funding exhaustion
Based on reported figures, AMIX trades at a price-to-book ratio of 0.33, which suggests that the market is heavily discounting the company's intellectual property and future commercial potential relative to the capital invested in its clinical-stage medical device development platform.
The low P/B multiple indicates that investors are pricing in significant execution risk and the high probability of future dilution. Given the company is pre-revenue, traditional valuation metrics like P/E or EV/EBITDA are inapplicable, leaving the market to value the firm primarily as a speculative option on its proprietary sensing technology.
According to recent SEC filings, the company's current ratio has fluctuated significantly, settling at 4.45 in 2026Q4, which, while appearing numerically high, masks the reality of a rapidly depleting cash position that must sustain ongoing clinical trial operations without any incoming revenue.
The high current ratio is a function of the company's cash-heavy asset base rather than operational efficiency. Investors should monitor the burn rate closely, as the lack of revenue means that liquidity is strictly a function of the remaining cash balance, which provides limited runway for unexpected regulatory or clinical setbacks.
As reported in financial statements, the company's asset turnover and working capital metrics are currently data unavailable, reflecting the firm's status as a pre-revenue entity that has yet to establish a commercial supply chain or customer base to generate meaningful operational throughput.
The absence of standard efficiency ratios is expected for a development-stage firm, but it complicates the assessment of how effectively management will eventually convert capital into revenue. Future analysis should focus on the cash conversion cycle once commercialization begins to determine if the microchip-enabled catheter model can achieve sustainable margins.
As indicated by the company's financial statements, analysts frequently misapply net margin and ROE to AMIX, which obscures the fact that these metrics are currently negative by design as the firm prioritizes R&D investment over immediate profitability during its critical clinical validation phase.
Using standard profitability ratios to evaluate AMIX is misleading because they penalize the company for the very R&D spending required to build its competitive moat. A more appropriate framework would involve tracking clinical milestone progress relative to cash burn, rather than focusing on accounting losses that are inherent to the current business model.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMIX stock.
Autonomix Medical, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Autonomix Medical, Inc.'s return on equity (ROE) is -238.9%. The historical average is -227.5%.
Based on historical data, Autonomix Medical, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.